Literature DB >> 2897559

Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections.

I M Hoepelman1, M Rozenberg-Arska, J Verhoef.   

Abstract

To compare the efficacy of once daily monotherapy with that of standard combination antibiotic therapy for the initial management of patients suspected of serious bacterial infections, 105 patients were randomised to treatment with ceftriaxone alone (53 patients) or to a combination of cefuroxime and gentamicin (52 patients). There was no difference between the groups in proportions responding to therapy or proportions dying from infection, except when non-evaluable patients were excluded from the group with definite bacterial infection, in which case response was better among those treated with ceftriaxone. The groups did not differ in number of side-effects, but therapy had to be discontinued because of treatment failure, an adverse effect, or death in 1 of 53 patients given ceftriaxone and in 11 of 34 given the combination. Use of ceftriaxone was 107.36 pounds ($182.51) cheaper per patient, and saved 40 minutes of nursing and drug administration time per patient per day. Thus 2 g ceftriaxone given once a day is at least as effective and costs less in time and money than gentamicin plus cefuroxime for the initial treatment of patients with serious systemic bacterial infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897559     DOI: 10.1016/s0140-6736(88)92121-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 2.  Human insulin.

Authors:  J Pickup
Journal:  BMJ       Date:  1989-10-21

3.  An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.

Authors:  E T Smyth; J G Barr; C A O'Neill; G M Hogg
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

4.  Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients.

Authors:  C A Jaspers; H Kieft; B Speelberg; A Buiting; M van Marwijk Kooij; G J Ruys; H H Vincent; M C Vermeulen; A G Olink; I M Hoepelman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

6.  Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.

Authors:  L Leibovici; M Paul; O Poznanski; M Drucker; Z Samra; H Konigsberger; S D Pitlik
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Ceftriaxone protects against tobramycin nephrotoxicity.

Authors:  D Beauchamp; G Thériault; L Grenier; P Gourde; S Perron; Y Bergeron; L Fontaine; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.

Authors:  H Kieft; A I Hoepelman; M Rozenberg-Arska; J M Branger; J H Voskuil; A B Geers; M Kluyver; H C Hart; E Poest-Clement; L van Beugen
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 9.  Impact of dosage schedule of antibiotics on the treatment of serious infections.

Authors:  I A Bakker-Woudenberg; R Roosendaal
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 10.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.